Efficacy of Low- and High-Dose Trilostane Treatment in Dogs (< 5 kg) with Pituitary-Dependent Hyperadrenocorticism
Open Access
- 20 November 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 27 (1) , 91-98
Abstract
Background: Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH. Objectives: To compare the efficacy of 2 trilostane protocols in the treatment of dogs with PDH. Animals: Sixteen client-owned dogs with PDH and a body weight <5 kg. Methods: Prospective observational study. Group A (n=9; low-dose treatment group) received 0.78 ± 0.26 mg of trilostane/kg PO every 12 h and group B (n = 7; high-dose treatment group) 30 mg of trilostane/dog PO every 24 h. All of the dogs were reassessed at 2, 4, 8, 12, 16, and 24 weeks after the initiation of treatment. Results: An improvement in both ACTH-stimulated serum cortisol concentrations and clinical signs occurred more slowly in group A than in group B; however, after 20 weeks of treatment, 2/7 dog in group B had clinical signs and abnormal laboratory findings consistent with hypoadrenocorticism. At 24 weeks, an improvement in the clinical findings of all of the dogs in both groups was detected. Conclusions and clinical importance: In dogs with PDH, twice-daily administration of low-dose trilostane is an effective approach to the management of PDH. In addition, our results suggest fewer potential adverse effects if trilostane is administered twice daily in the lower dose.Keywords
Funding Information
- Ministry of Education, Science and Technology (2011-0031403)
This publication has 27 references indexed in Scilit:
- Evaluation of twice-daily lower-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticismJournal of the American Veterinary Medical Association, 2011
- Monitoring the response of canine hyperadrenocorticism to trilostane treatment by assessment of acute phase protein concentrationsJournal of Small Animal Practice, 2010
- Use of ketoconazole to treat dogs with pituitary-dependent hyperadrenocorticism: 48 cases (1994–2007)Journal of the American Veterinary Medical Association, 2008
- Persistent isolated hypocortisolism following brief treatment with trilostaneAustralian Veterinary Journal, 2008
- Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticismJournal of the American Veterinary Medical Association, 2008
- Long-Term Efficacy of Trilostane Administered Twice Daily in Dogs With Pituitary-Dependent HyperadrenocorticismJournal of the American Animal Hospital Association, 2006
- Diagnosis of Canine HyperadrenocorticismVeterinary Clinics of North America: Small Animal Practice, 1997
- Mitotane (o, p‘-DDD) Treatment of 200 Dogs with Pituitary-Dependent HyperadrenocorticismJournal of Veterinary Internal Medicine, 1991
- Canine Hyperadrenocorticism Due to Adrenocortical Neoplasia: Pretreatment Evaluation of 41 DogsJournal of Veterinary Internal Medicine, 1991
- Trilostane, an orally active inhibitor of steroid biosynthesisSteroids, 1978